Craft Health's CraftMake Platform Runs Peptide-Dosing Test With PharmaTher Ahead of FDA 503A Bulks List Decision

Singapore's Craft Health is testing its CraftMake 3D printing platform on six peptides, BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, under a collaboration with PharmaTher Holdings announced July 29, 2026, two days after PharmaTher launched its Personaliz3D Peptides division. CraftMake prints via semi-solid paste extrusion at room temperature, avoiding the heat and UV exposure that can degrade peptide actives, and can produce multi-material pill-in-pill doses for staged release. The GMP-oriented CraftMake Production Plus variant runs in an enclosed, dual-printhead environment with roughly 1% dosing accuracy and repeatability above 99%.

The six peptides are candidates the FDA's Pharmacy Compounding Advisory Committee recently recommended for the Section 503A Bulks List, which would let compounding pharmacies use them under existing rules rather than full drug approval. PharmaTher is lining up 3D printing as the manufacturing method ahead of that recommendation being adopted, pairing dose personalization with GMP controls that compounding pharmacies don't uniformly carry. CraftControl handles no-code print jobs and audit trails, and the CraftBlends database covers immediate, delayed, sustained, and orally disintegrating release profiles, positioning Craft Health as a software-plus-hardware pharmaceutical platform rather than a printer vendor alone.

The deal's near-term value hinges on that PCAC recommendation being formally adopted, since 503A pharmacies cannot legally compound these peptides until it is. Craft Health does not appear in the AMPulse company index, an absence that reflects incomplete coverage rather than company scale.